Repositioning Candidate Details
Candidate ID: | R0961 |
Source ID: | DB06256 |
Source Type: | investigational |
Compound Type: | biotech |
Compound Name: | rPSGL-Ig |
Synonyms: | rPSGL-Ig; YSPSL |
Molecular Formula: | -- |
SMILES: | -- |
DrugBank Description: | Recombinant P-selectin glycoprotein ligand IgG fusion protein (rPSGL-Ig) is a fusion protein of human P-selectin ligand and IgG1-Fc. |
CAS Number: | -- |
Molecular Weight: | |
DrugBank Indication: | Investigated for use/treatment in myocardial infarction, red blood cell disorders, anemia, kidney transplant surgery, transplant (rejection), liver transplant surgery, and ischemic reperfusion injury. |
DrugBank Pharmacology: | -- |
DrugBank MoA: | -- |
Targets: | -- |
Inclusion Criteria: | Indication associated |

Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
---|
Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
---|
Diseases ID | DO ID | Disease Name | Definition | Class | |
---|---|---|---|---|---|
I08 | 114 | Cardiovascular system disease | A disease of anatomical entity which occurs in the blood, heart, blood vessels or the lymphatic system that passes nutrients (such as amino acids and electrolytes), gases, hormones, blood cells or lymph to and from cells in the body to help fight diseases and help stabilize body temperature and pH to maintain homeostasis. http://en.wikipedia.org/wiki/Circulatory_system | disease of anatomical entity | Details |